More specifically, by taking advantage of the high affinity interaction between mesothelin and MUC16 [27], we recently designed a mesothelin/TR3 fusion protein, designated Meso-TR3, in order to tether our therapeutic to the MUC16 biomarker located on the tumor cell membrane [28]. The gene discussed is MSLN; the disease is neoplasm.